Researchers analyze prostate cancer incidence over 20 years in men aged 45-70 years without prostate cancer and identify ...

PSA and Ki-67 tumour markers may identify high-risk metastatic castration-sensitive prostate cancer and inform treatment ...

Opportunistic prostate cancer screening can lead to overdiagnosis of indolent diseases and invasive procedures. A cohort ...

Unfortunately, you’re not able to donate blood today. Not until you’re cancer-free for at least a year. Just on the outside ...

A real-world study found Erleada reduced the risk of death compared with Nubeqa in patients with metastatic ...

Johnson & Johnson today announced new real world head-to-head evidence demonstrating that patients with metastatic castration-sensitive prostate cancer (mCSPC) initiating ERLEADA® without docetaxel ...

Listen to Jacksonville’s Morning News every Friday for good news in Jacksonville, presented by UF Health Proton Therapy ...

Prostate cancer (PCa) remains a significant global health challenge, with rising morbidity rates and poor prognosis associated with advanced stages ...

Drs Dean Ornish and Peter Carroll presented their research on the effects of an intensive lifestyle program on outcomes for ...

Investigators tested a new neoadjuvant immunotherapy to fight prostate cancer using a virus-mimicking drug to activate the immune system.

Novartis, a leading global innovative medicines company and the official pharmaceutical partner of the NFL, today announced the launch of "Relax, it's a blood test," a new national prostate cancer ...

This clinical overview details the latest evidence-based strategies for diagnosing and treating symptoms of benign prostatic hyperplasia in men.